Valion Bio, Inc.

Stage 4 · Declining · week 20

As of Oct 22, 2026, Valion Bio is in Stage 4, the downtrend phase, now in week 20 (since Jun 4, 2026). It closed at $0.96, 98.7% below its 52-week high and below its 200-day average, which is falling.

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. More about the company

$0.96

-14.64% today

$1.9M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is VBIO early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 18w

S4 47w

S4 42w

S4 20w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 18w → S1 6w → S4 47w → S1 4w → S4 2w → S1 3w → S2 1w → S1 1w → S4 11w → S1 4w → S4 42w → S1 5w → S4 20w current

Total tracked: 166 weeks across 13 stage runs.

VBIO among Biotechnology548th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…548	VBIOValion Bio, Inc.	Stage 4 · wk 20	3	−65.0%

vs 52W High

-98.7%

$0.96 lo$72.25 hi

98.7% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 20

1w13w26w

Week 20, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-94.1%

200 DMA: $16.08 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.08x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-65.0%

-87.1%

-96.6%

YTD

-97.3%

-98.7%

Scan Membership

Breakout Watch

Latest: 2025-03-06

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 20 · Vol 0.08x

2026-10-21S4

Wk 20 · Vol 0.09x

2026-10-20S4

Wk 20 · Vol 0.03x

2026-10-19S4

Wk 19 · Vol 0.06x

2026-10-16S4

Wk 19 · Vol 0.13x

2026-10-15S4

Wk 19 · Vol 7.35x

2026-10-14S4

Wk 19 · Vol 0.09x

2026-10-13S4

Wk 19 · Vol 0.10x

2026-10-12S4

Wk 18 · Vol 0.13x

2026-10-09S4

Wk 18 · Vol 0.08x

2026-10-08S4

Wk 18 · Vol 0.08x

2026-10-07S4

Wk 18 · Vol 0.07x

Moving averages & range

50 DMA

$2.62

200 DMA

$16.08

52W High

$72.25

52W Low

$0.96

5D Low

$0.96

Resistance levels (recent highs)

20d High

$3.03

60d High

$8.30

120d High

$27.75

250d High

$72.25

Next resistance

+216.9%

to 20d High

ROE

-459.5%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 0.0

Valion Bio: quick answers

What stage is Valion Bio in?

As of Oct 22, 2026, Valion Bio (VBIO) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 4, 2026 and is in week 20. What the four stages mean

Is Valion Bio in an uptrend?

No. Valion Bio is in a Stage 4 downtrend. It trades 94.1% below its 200-day average, which is falling.

How far is Valion Bio from its 52-week high?

Valion Bio closed at $0.96 on Oct 22, 2026, 98.7% below its 52-week high of $72.25. Its 52-week low is $0.96.

How has Valion Bio performed over the past year?

As of Oct 22, 2026, Valion Bio is down 98.7% over the past year and down 97.3% so far in 2026.

Which sector and industry is Valion Bio in?

Valion Bio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.